BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Gilead Sciences Ltd. 

2 Roundwood Avenue
South Building - Stockley Park
Uxbridge  Middlesex  UB11 1AZ  United Kingdom
Phone: 44-0-208-587-2200 Fax: 44-0-208-744-6773


Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Kristen Metza, Senior Vice President, Human Resources
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Senior Director, Public Affairs

 Key Statistics

Ownership: Public

Web Site: Gilead Sciences Ltd.
Employees: 3,200
Symbol: GILD

 Company News
Roy D. Baynes, MD, PhD, to Join Gilead Sciences Ltd. (GILD) as Senior Vice President, Oncology Therapeutics Network 1/19/2012 6:19:58 AM
Gilead Sciences Ltd. (GILD) Completes Acquisition of Pharmasset, Inc. (VRUS) 1/18/2012 5:58:07 AM
AHF Slams Gilead Sciences Ltd. (GILD) “HIV Prevention Pill” FDA Application 12/16/2011 9:37:56 AM
Gilead Sciences Ltd. (GILD) Seeks First-ever Approval for Drug to Prevent HIV 12/16/2011 7:13:17 AM
AHF Salutes on Gilead Sciences Ltd. (GILD) on Price Cuts for US AIDS Drug Program 12/6/2011 7:43:32 AM
Gilead Sciences Ltd. (GILD) to Present at the 2011 Credit Suisse Healthcare Conference on Wednesday, November 9 11/9/2011 6:43:09 AM
Gilead Sciences Ltd. (GILD) Submits NDA to FDA for Quad Tablet 10/28/2011 7:10:33 AM
Gilead Sciences Ltd. (GILD) and GlobeImmune, Inc. Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection 10/25/2011 9:07:48 AM
Gilead Sciences Ltd. (GILD) Announces Second Quarter 2011 Financial Results 7/27/2011 8:13:49 AM
Gilead Sciences Ltd. (GILD) to Present at the 31st Annual William Blair & Company Growth Stock Conference on Wednesday, June 15 6/9/2011 9:33:26 AM